ライフサイエンスコーパス: respiratory tract

1 to check that they originated from the lower respiratory tract.

2 ially contribute to the morphogenesis of the respiratory tract.

3 splayed significant virulence in the chicken respiratory tract.

4 allenge virus replication was reduced in the respiratory tract.

5 ated with disease manifestations outside the respiratory tract.

6 und or extracellular serine proteases in the respiratory tract.

7 eptors that are usually present in the human respiratory tract.

8 tion with the replication in the human upper respiratory tract.

9 ns thus far, being recovered mainly from the respiratory tract.

10 wn whether it causes oxidative stress in the respiratory tract.

11 pressing inflammatory processes of the upper respiratory tract.

12 ed by an unidentified infection of the upper respiratory tract.

13 h to be inhaled and deposited throughout the respiratory tract.

14 e epithelial lining fluid (ELF) of the human respiratory tract.

15 spiratory infection progressing to the lower respiratory tract.

16 e stresses, which are present throughout the respiratory tract.

17 matrix protein ubiquitously expressed in the respiratory tract.

18 al tissues, including the female genital and respiratory tract.

19 in, and reduced bacterial recovery from, the respiratory tract.

20 rols differ in bacterial colonization of the respiratory tract.

21 N2:pH1N1 (P7) virus replicated in the entire respiratory tract.

22 educed RSV loads in both the upper and lower respiratory tracts.

23 roconverted, and virus was detected in their respiratory tracts.

24 re than 1129 did in both the upper and lower respiratory tracts.

25 superficial tissue (66.5%), followed by the respiratory tract (17.4%).

26 rect the immune system and components of the respiratory tract along pathways that allow asthma to be

27 phen induced oxidative stress throughout the respiratory tract and appeared to potentiate some respon

28 aerosols of virus would penetrate the lower respiratory tract and blanket alveoli where target cells

29 y Aspergillus flavus, which can colonize the respiratory tract and cause fungal rhinosinusitis or bro

30 ssis is a human pathogen that can infect the respiratory tract and cause the disease known as whoopin

31 pha, interleukin-6, and interleukin-8 in the respiratory tract and central nervous system.

32 conferred increased viral replication in the respiratory tract and elevated respiratory droplet trans

33 There was also evidence of spread beyond the respiratory tract and fecal shedding.

34 ession of HOXA5 protein in mesenchyme of the respiratory tract and in phrenic motor neurons of the ce

35 looks at the landscape ecology of the upper respiratory tract and mouth and seeks greater clarity ab

36 fficient clearance of virus within the upper respiratory tract and rarely produces severe disease.

37 virus, an acute infection that begins in the respiratory tract and spreads by viremia to internal org

38 H9 viruses infected the upper and lower respiratory tract and the majority of H9 viruses had a d

39 HBoV1 infects the respiratory tract, and HBoV3 and HBoV4 infect the gastro

40 uced viral titers, particularly in the lower respiratory tract, and substantially alleviated disease

41 by aerosol immunization targeting the lower respiratory tract, and that S-FLU is a promising univers

42 Cultures of skin, respiratory tract, and the perianal area were obtained f

43 against RSV infection in the upper and lower respiratory tract at a dose of 10(6) PFU of vaccine.

44 In critical care patients, we observed that respiratory tract bacterial colonisation is significantl

45 ERS-CoV) targets the epithelial cells of the respiratory tract both in humans and in its natural host

46 he topography and population dynamics of the respiratory tract, both in health and as altered by acut

47 panin CD151 is highly expressed in the human respiratory tract, but its pathological role in IAV infe

48 Infections of the respiratory tract can be caused by a diversity of pathog

49 Molecular detection of RVs from the upper respiratory tract can be prolonged, complicating etiolog

50 examined whether rhinovirus infection of the respiratory tract can block airway tolerance by modulati

51 nical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persiste

52 toxin (ACT or CyaA) plays a crucial role in respiratory tract colonization and virulence of the whoo

53 ility to early allergic sensitization, upper respiratory tract colonization with bacterial pathogens,

54 iation between colonization density of upper respiratory tract colonizers and pathogen-specific pneum

55 ract, with an infant receiving much of their respiratory tract deposited dose in their lower airways.

56 ant will receive a nearly four times greater respiratory tract deposited dose of resuspended FBAPs co

57 es infant and adult inhalation exposures and respiratory tract deposited dose rates of resuspended bi

58 Lower respiratory tract disease can manifest itself as airflow

59 irus (hRSV) is responsible for serious lower respiratory tract disease in infants and in older adults

60 st important viral agent of severe pediatric respiratory tract disease worldwide, but it lacks a lice

61 en with acute respiratory failure from lower respiratory tract disease, an extubation readiness test,

62 tial virus (RSV) is a leading cause of lower respiratory tract disease, which causes high rates of mo

63 en with acute respiratory failure from lower respiratory tract disease.

64 ng invasive mechanical ventilation for lower respiratory tract disease.

65 nd resistance to treatment of multiple human respiratory tract diseases including otitis media, chron

66 rder, cardiovascular diseases, chronic lower respiratory tract diseases, liver cirrhosis, and spinal

67 was selectively enhanced in the human lower respiratory tract during a seasonal outbreak dominated b

68 ounty were estimated for uncomplicated upper respiratory tract encounters (acute otitis media, pharyn

69 Of 246866 uncomplicated upper respiratory tract encounters, antibiotics were dispensed

70 ruses, especially H3N2 viruses, in the human respiratory tract have remain undefined despite many yea

71 and all 20 viruses replicated throughout the respiratory tract; however, replication in the lungs was

72 s the most common cause of viral acute lower respiratory tract illness (LRTI) in young children, and

73 pitalizations and deaths due to severe lower respiratory tract illness (LRTI) were recorded during th

74 hundred and fifty (29%) infants had a lower respiratory tract illness during the first year of life.

75 spiratory syncytial virus (RSV) causes lower respiratory tract illness frequently.

76 Early life lower respiratory tract illness impairs lung function at 1 yea

77 ononegavirales) is one of the main causes of respiratory tract illness in children.

78 coccal load in blood was not associated with respiratory tract illness in controls (P = .32).

79 RATIONALE: Lower respiratory tract illness is a major cause of childhood

80 Preventing early life lower respiratory tract illness is important to optimize lung

81 Lower respiratory tract illness surveillance was performed and

82 Lower respiratory tract illness was independently associated w

83 act of early life exposures, including lower respiratory tract illness, on lung function during infan

84 se group, or number of parent-reported upper respiratory tract illnesses between groups (625 for high

85 ninfluenza infections, parent-reported upper respiratory tract illnesses, time to first upper respira

86 otection from virus replication in the lower respiratory tract.IMPORTANCE RSV disease is of great imp

87 lly associated with specimens from the lower respiratory tract in adults.

88 wheeze or asthma and infections of the lower respiratory tract in offspring by approximately 7 percen

89 a (13 [12%]), headache (11 [10%]), and upper respiratory tract infection (11 [10%]).

90 ction (19 [7%] vs 11 [4%] vs 13 [5%]), upper respiratory tract infection (15 [5%] vs 15 [5%] vs 11 [4

91 ost common adverse events overall were upper respiratory tract infection (51 [9%] of 581 patients rec

92 ts were fatigue (25%), headache (13%), upper respiratory tract infection (8%), and arthralgia (8%).

93 t hospitalizations for all-cause acute lower respiratory tract infection (ALRI).

94 elines on antibiotic prescriptions for acute respiratory tract infection (ARTI) in PEDs.

95 Acute respiratory tract infection (ARTI) is the most common re

96 ild diarrhea (in 52% of the patients), upper respiratory tract infection (in 48%), nausea (in 47%), a

97 Lower respiratory tract infection (LRTI) commonly causes hospi

98 iratory tract infection (URTI) without lower respiratory tract infection (LRTI), URTI progressing to

99 common reason for hospitalization was lower respiratory tract infection (LRTI).

100 nificance remains unclear in pediatric lower respiratory tract infection (LRTI).

101 vents in both groups were headache and upper respiratory tract infection (ten [16%] for both events i

102 s completed daily from the onset of an upper respiratory tract infection (URTI) until asthma symptom

103 e grouped according to the presence of upper respiratory tract infection (URTI) without lower respira

104 d high risk of future hospital admission for respiratory tract infection and could be used to reduce

105 y elective CS had an increased risk of lower respiratory tract infection and juvenile idiopathic arth

106 months and 12 years diagnosed with an acute respiratory tract infection and prescribed an oral antib

107 didates were efficacious in preventing lower respiratory tract infection as well as in reducing the n

108 lated from nasal lavage fluid during a viral respiratory tract infection expressed CysLTR1.

109 ects of oral corticosteroids for acute lower respiratory tract infection in adults without asthma.

110 ruses (RVs) are a major cause of symptomatic respiratory tract infection in all age groups.

111 ocavirus (HBoV) 1 can cause life-threatening respiratory tract infection in children.

112 re present during symptoms of an acute viral respiratory tract infection in human subjects.

113 RSV and hMPV are the leading causes of acute respiratory tract infection in infants and children.

114 the most prevalent worldwide cause of severe respiratory tract infection in infants and young childre

115 syncytial virus (RSV) is a leading cause of respiratory tract infection in infants, causing signific

116 rus (hRSV) is a leading cause of acute lower respiratory tract infection in infants, elderly and immu

117 us (RSV) is the most frequent cause of lower respiratory tract infection in infants.

118 efficiently inhibits established acute lower respiratory tract infection in the animals, even when tr

119 the pitavastatin group (n=12, 10%) and upper respiratory tract infection in the pravastatin group (n=

120 tial virus (RSV) is a leading cause of lower respiratory tract infection in young children worldwide.

121 cytial virus is a major cause of acute lower respiratory tract infection in young children, immunocom

122 s pneumoniae, the transition to severe lower respiratory tract infection is associated with an increa

123 Acute lower respiratory tract infection is common and often treated

124 Respiratory syncytial virus (RSV) lower respiratory tract infection is implicated in asthma deve

125 g for viruses in children who present with a respiratory tract infection is to differentiate between

126 osteroids should not be used for acute lower respiratory tract infection symptoms in adults without a

127 es were duration and severity of acute lower respiratory tract infection symptoms, duration of abnorm

128 or duration or severity of other acute lower respiratory tract infection symptoms, duration of abnorm

129 One treatment-related death from a respiratory tract infection was reported in the docetaxe

130 sLTR1 signaling in the first days of a viral respiratory tract infection was sufficient to reduce acc

131 one focal and one systemic symptom of acute respiratory tract infection were assigned 1:1 to receive

132 Patients with severe acute respiratory tract infection were excluded.

133 pansion of CD8(+) T cells following an upper respiratory tract infection with a pathogenic influenza

134 dex was found to be a robust marker of viral respiratory tract infection with a sensitivity of 80% an

135 The outcome was hospital admission for respiratory tract infection within 30 days, collected us

136 verse events were injection-site pain, upper respiratory tract infection, and nausea.

137 %]), febrile neutropenia (five [10%]), lower respiratory tract infection, and pneumonia (each three [

138 iratory tract illnesses, time to first upper respiratory tract infection, and serum 25-hydroxyvitamin

139 d placebo groups were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF; and t

140 used Bordetella pertussis, a common neonatal respiratory tract infection, as a proof of concept to in

141 60 yr) patients in health and during a lower respiratory tract infection, community-acquired pneumoni

142 The most frequent AEs were fatigue, upper respiratory tract infection, cough, and dyspnea.

143 ypically young children with upper and lower respiratory tract infection, presenting with symptoms in

144 act animals demonstrated various symptoms of respiratory tract infection, they were mild, and the cal

145 Subject Headings terms: "acute bronchitis," "respiratory tract infection," "pharyngitis," "rhinosinus

146 Asthma-, allergy-, and respiratory tract infection-associated phenotypes (inclu

147 thelial secretome participating in RSV lower respiratory tract infection-induced airway remodeling.

148 vg+) phase that are necessary for successful respiratory tract infection.

149 on following a primary diagnosis of an upper respiratory tract infection.

150 rs), 414 (47%) were women, and 379 (43%) had respiratory tract infection.

151 for Haemophilus colonization and subsequent respiratory tract infection.

152 ial virus (HRSV) is a major cause of serious respiratory tract infection.

153 at resulted in two bacteremias and one lower respiratory tract infection.

154 elop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial virus

155 two studies, 1 681 020 events) and for lower respiratory tract infections (-18.48% [-32.79 to -4.17];

156 s), and rates of hospital attendance for all respiratory tract infections (-3.45% [-4.64 to -2.25]; t

157 on (343 [45%] infections), followed by lower respiratory tract infections (171 [22%]), gastrointestin

158 h dupilumab compared with placebo were upper respiratory tract infections (33-41% vs 35%) and injecti

159 riate antibiotic prescribing for acute upper respiratory tract infections (AURIs) requires a better u

160 eight [8%] patients in each group) and upper respiratory tract infections (five [5%] patients in each

161 Common grade 1-2 toxicities included upper respiratory tract infections (in 28 [57%] of 49 patients

162 urden of severe human metapneumovirus (HMPV) respiratory tract infections (RTIs) in European children

163 ota stability and thereby resistance against respiratory tract infections (RTIs) over time.

164 fection rates, and identify risk factors for respiratory tract infections (RTIs).

165 Acute respiratory tract infections account for the majority of

166 three common viruses implicated in seasonal respiratory tract infections and are a major cause of mo

167 general nontuberculosis morbidity, including respiratory tract infections and atopic diseases.

168 Bacterial respiratory tract infections and exacerbations of chroni

169 esent in the nasal mucosa during acute viral respiratory tract infections and further characterize th

170 teroid-insensitive asthma is associated with respiratory tract infections and noneosinophilic endotyp

171 , influenza, and respiratory syncytial virus respiratory tract infections and ovalbumin-induced, seve

172 ietary supplements, primarily to treat upper respiratory tract infections and to support immune funct

173 Viral respiratory tract infections are associated with asthma

174 Respiratory tract infections are frequent causes of hosp

175 Respiratory tract infections are one of the leading caus

176 Viral respiratory tract infections are the main causative agen

177 Viral respiratory tract infections are the most common human a

178 e number of laboratory-confirmed viral upper respiratory tract infections based on parent-collected n

179 While most viral respiratory tract infections can be diagnosed clinically

180 ice with TP73 deficiency suffer from chronic respiratory tract infections due to profound defects in

181 9% women) for antibiotic-inappropriate acute respiratory tract infections during the baseline period

182 ation study and subsequent symptoms of lower respiratory tract infections during the first year of li

183 Lower respiratory tract infections from respiratory syncytial

184 -level proportion of prescriptions for upper respiratory tract infections in 2-14-year-old outpatient

185 RSV) is the leading etiologic agent of lower respiratory tract infections in children, but no license

186 (hRSV) is the leading cause of severe lower respiratory tract infections in children.

187 rrow-spectrum antibiotic treatment for acute respiratory tract infections in children.

188 served in vivo and the occurrence of chronic respiratory tract infections in immunocompromised hosts.

189 he most common viruses associated with acute respiratory tract infections in infancy.

190 al virus (RSV) is the leading cause of lower respiratory tract infections in infants, a safe and effe

191 al virus (RSV) is the leading cause of lower respiratory tract infections in the very young.

192 RSV is a major cause of serious lower respiratory tract infections in young children and cause

193 HBoV1 causes acute respiratory tract infections in young children and has a

194 emerging respiratory virus that causes lower respiratory tract infections in young children worldwide

195 single most important cause of serious lower respiratory tract infections in young children, yet no h

196 on reduces the incidence of wintertime upper respiratory tract infections in young children.

197 1 (HBoV1), a human parvovirus, causes lower respiratory tract infections in young children.

198 oV1) is a human parvovirus that causes acute respiratory tract infections in young children.

199 ytial virus (RSV) is the main cause of lower respiratory tract infections in young children.

200 BoV1) is pathogenic to humans, causing acute respiratory tract infections in young children.

201 Multiplex tests for respiratory tract infections include up to 20 targets fo

202 Viral respiratory tract infections increase the risk of develo

203 Inappropriate antibiotic use for acute respiratory tract infections is common in primary health

204 ad-spectrum antibiotic prescribing for acute respiratory tract infections is increasing.

205 he mean number of laboratory-confirmed upper respiratory tract infections per child was 1.05 (95% CI,

206 Atopy and viral respiratory tract infections synergistically promote ast

207 Respiratory tract infections were most common and were d

208 nd susceptibility to allergic sensitization, respiratory tract infections, and asthma.

209 r respiratory tract infections, severe lower respiratory tract infections, and exacerbations of under

210 Infusion-related reactions, upper respiratory tract infections, and oral herpes infections

211 and the secondary end points included lower respiratory tract infections, asthma exacerbations, ecze

212 Among children with acute respiratory tract infections, broad-spectrum antibiotics

213 ied a child with life-threatening, recurrent respiratory tract infections, caused by viruses includin

214 , stinging insects, fungi, pollutants, viral respiratory tract infections, climate change, and microb

215 HBoV1 is pathogenic to humans, causing acute respiratory tract infections, especially in young childr

216 Adverse events were manageable and included respiratory tract infections, gastrointestinal symptoms,

217 considering prevention or treatment of viral respiratory tract infections, potential targets include

218 ized adults varies widely and includes upper respiratory tract infections, severe lower respiratory t

219 ral, bacterial, or fungal pathogens, such as respiratory tract infections, this necessitates large pa

220 a exacerbations, and hospital attendance for respiratory tract infections.

221 in D levels and a higher risk of viral upper respiratory tract infections.

222 ide and represent the leading cause of upper respiratory tract infections.

223 sitive and culture-negative sepsis and lower respiratory tract infections.

224 f future hospital admission in children with respiratory tract infections.

225 appropriate antibiotic prescribing for acute respiratory tract infections.

226 the appropriate use of antibiotics for acute respiratory tract infections.

227 articular concern in the management of lower respiratory tract infections.

228 rum antibiotics for most children with acute respiratory tract infections.

229 n children for the prevention of viral upper respiratory tract infections.

230 escribing of antibiotics for childhood upper respiratory tract infections.

231 ae (NTHI) is the causative agent of multiple respiratory tract infections.

232 tion did not reduce overall wintertime upper respiratory tract infections.

233 ospitalized patients <2 years old with lower respiratory tract infections.

234 gic association in persons with severe lower respiratory tract infections.

235 Eighteen (86%) patients were treated for respiratory tract infections; others were treated for bl

236 y-confirmed antibiotic-resistant urinary and respiratory-tract infections are more likely to experien

237 a major causative agent of upper- and lower-respiratory-tract infections in infants, the elderly, an

238 Upper respiratory tract inflammatory diseases such as asthma a

239 ubiquitous environmental pollutant, in human respiratory tract is a subject of intense debate.

240 ecretion of this protease in the human lower respiratory tract is enhanced during influenza.

241 The human respiratory tract is exposed daily to airborne fungi, fu

242 The respiratory tract is heavily populated with innate immun

243 ial was measured on the basis of a synthetic respiratory tract lining fluid containing the antioxidan

244 r kinase, PlrS [for persistence in the lower respiratory tract (LRT) sensor], which is required for B

245 prehensive molecular testing of single lower respiratory tract (LRT) specimens achieved pathogen dete

246 avirus for viral load in the lower and upper respiratory tracts (LRT and URT, respectively), blood, s

247 ure, and crowding conditions, in relation to respiratory tract microbiota maturation and stability, a

248 e is a key step during colonization of human respiratory tract mucosae.

249 acterial communities at 2 sites of the upper respiratory tract obtained from children from a rural ar

250 ting at low titers over several days, in the respiratory tract of African green monkeys (AGMs).

251 used by other pathogens carried in the upper-respiratory tract of children.

252 ability of the mutant to colonize the lower respiratory tract of mice.

253 fy the prevalence of 13 viruses in the upper respiratory tract of patients with CAP and concurrently

254 le in facilitating colonization of the upper respiratory tract of rhesus macaques, in some cases asso

255 s was found to enhance survival in the lower respiratory tract of swine.

256 not be required for persistence in the upper respiratory tract of swine.

257 ribution of influenza virus receptors in the respiratory tract of the microminipig was similar to tha

258 must then be released as an aerosol via the respiratory tract of the source case.

259 MERS-CoV replication in the upper and lower respiratory tracts of camels and humans, respectively.

260 The prevalence of fungi in the respiratory tracts of cystic fibrosis (CF) patients has

261 bacterial species that is found in the upper respiratory tracts of pigs and can also cause Glasser's

262 gi are directly allergenic by colonising the respiratory tract or indirectly through contact with cel

263 dy was to determine if acetaminophen induces respiratory tract oxidative stress and/or potentiates th

264 PRELP specifically binds respiratory tract pathogens Moraxella catarrhalis, Haemo

265 RAF fusion found in a vemurafenib-refractory respiratory tract PMM, from which cell line harboring ZN

266 Confirmation of RSV infection in the lower respiratory tract provides prognostic information that m

267 The lymphoid tissue that drains the upper respiratory tract represents an important induction site

268 cts of acetaminophen on oxidant and irritant respiratory tract responses to environmental tobacco smo

269 LRTI was defined as a positive lower respiratory tract sample with or without radiographic ab

270 able LRTI, respectively) or a positive upper respiratory tract sample with radiographic abnormality (

271 Among 3263 respiratory tract samples, 24.5% (798) and 37.3% (1216)

272 cells are regarded as indicative of a lower respiratory tract specimen.

273 The most common virus detected in upper respiratory tract specimens was EV-D68 (from 20%, and 47

274 ificity (eg, detection of pathogens in upper respiratory tract specimens, which may indicate asymptom

275 adults with acute cough and at least 1 lower respiratory tract symptom not requiring immediate antibi

276 ting variant angina that manifested as a non-respiratory tract symptom of aspirin-exacerbated respira

277 etent children presenting with typical viral respiratory tract symptoms, the diagnosis can be made cl

278 viruses (IAVs) cause acute infection of the respiratory tract that affects millions of people during

279 why the virus efficiently replicates in the respiratory tract that exhibits high levels of this isof

280 nificant life stage outside of the mammalian respiratory tract that has yet to be defined.

281 luenza A virus infection is initiated in the respiratory tract, the sequence of events and the cell t

282 The distribution of DPP4 in the respiratory tract tissues of humans and camels reflects

283 nd CYP2F1 in NA bioactivation and NA-induced respiratory tract toxicity in mouse models.

284 re they play significant roles in NA-induced respiratory tract toxicity.

285 man lung CYP2A13 and CYP2F1 can mediate NA's respiratory tract toxicity.

286 vel data on laboratory-confirmed infections (respiratory tract, urinary tract, skin or soft tissue),

287 The upper respiratory tract (URT) hosts a complex microbial commun

288 rence of identifying a pathogen in the upper respiratory tract (URT) of children with pneumonia is un

289 caused limited tissue pathology in the upper respiratory tract (URT).

290 an and avian H9 influenza virus in the human respiratory tract using ex vivo respiratory organ cultur

291 Our results suggest that respiratory tract viral infections are associated with d

292 se little is known about the contribution of respiratory tract viruses in this context, we evaluated

293 ed in regard to rhinovirus, as well as other respiratory tract viruses.

294 , DPP4 expression in epithelial cells of the respiratory tract was almost absent.

295 Replication beyond the respiratory tract was also evident, particularly in the

296 infectious disease and 2) infections of the respiratory tract, whereas a dose-response relationship

297 that a specimen representative of the lower respiratory tract will contain smaller quantities of oro

298 D151 in IAV infection of the upper and lower respiratory tracts with H1N1 and H3N2 strains.

299 )-10(4) resuspended FBAPs can deposit in the respiratory tract, with an infant receiving much of thei

300 ave SAalpha2,3Gal and SAalpha2,6Gal in their respiratory tracts, with similar distributions of both r